Alexandr Kolobnev, Amstel Gold Race 2011

Alexandr Kolobnev will have his Tour de France doping case heard at the Court of Arbitration for Sport on February 7, the organisation confirmed on Friday.

The CAS hearing is a result of an appeal lodged by the sport's governing body, the Union Cycliste Internationale (UCI), in response to the Russian cycling federation (FVSR) giving Kolobnev a warning and small fine for failing an anti-doping test at the 2011 Tour.

Kolobnev was fined just over £1,000 by FVSR, which said it had 'taken into account extenuating circumstances'. If CAS rules in favour of the UCI, Kolobnev will face a suspension from competition, usually two years in such cases.

Kolobnev tested positive for banned diuretic hydrochlorothiazide, which can be used as a masking agent for other banned substances, after stage five of the Tour in July. It was the only positive test of the race.

Kolobnev has not had his contract renewed with Katusha and is currently without a squad for 2012. He has not raced since leaving the Tour.

The Court of Arbitration for Sport are also due to give a final verdict at the end of January on the case of Alberto Contador's positive test for clenbuterol at the 2010 Tour de France.

Related links

UCI appeals Kolobnev's Tour de France dope case to CAS

Kolobnev avoids suspension for Tour de France doping positive

Kolobnev's Tour de France positive confirmed

Kolobnev tests positive at Tour de France

 

Thank you for reading 5 articles this month* Join now for unlimited access

Enjoy your first month for just £1 / $1 / €1

*Read 5 free articles per month without a subscription

Join now for unlimited access

Try first month for just £1 / $1 / €1

Nigel Wynn worked as associate editor on CyclingWeekly.com, he worked almost single-handedly on the Cycling Weekly website in its early days. His passion for cycling, his writing and his creativity, as well as his hard work and dedication, were the original driving force behind the website’s success. Without him, CyclingWeekly.com would certainly not exist on the size and scale that it enjoys today. Nigel sadly passed away, following a brave battle with a cancer-related illness, in 2018. He was a highly valued colleague, and more importantly, n exceptional person to work with - his presence is sorely missed.